IVF efficiency in different phenotypes of polycystic ovary syndrome

Abstract

Polycystic ovary syndrome occupies a leading place in the structure of endocrine infertility. This article presents the endocrine and metabolic features of the polycystic ovary syndrome phenotypes, as well as modern concepts of efficiency and complications of the use of assisted reproductive technologies, depending on the specific phenotype. The issues of polycystic ovary syndrome influence on selecting the method of assisted reproductive technologies, as well as possible complications that occur during in vitro fertilization and the features of the pregnancy course remain unresolved. The individualization of the approach seems to be promising when taking into account the differences in the hormonal profile and the features of metabolic disorders in each polycystic ovary syndrome phenotype. That may allow us to take one more step towards improving the effectiveness of in vitro fertilization and reducing the frequency of complications in patients with polycystic ovary syndrome.

Keywords

polycystic ovary syndrome / phenotype / insulin resistance / hyperandrogenemia / obesity / gestational diabetes mellitus / miscarriage / in vitro fertilization / ovarian hyperstimulation syndrome / efficiency

References

[1] Azziz R. Polycystic ovary syndrome. Obstet Gynecol. 2018;132(2):321–336. DOI: 10.1097/AOG.0000000000002698

[2] Azziz R. Polycystic ovary syndrome//Obstet. Gynecol. 2018. Vol. 132. No. 2. P. 321–336. DOI: 10.1097/AOG.0000000000002698

[3] Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057. DOI: 10.1038/nrdp.2016.57

[4] Azziz R., Carmina E., Chen Z. et al. Polycystic ovary syndrome//Nat. Rev. Dis. Primers. 2016. Vol. 2. P. 16057. DOI: 10.1038/nrdp.2016.57

[5] Abashova EI, Shalina MA, Misharina EV, et al. Clinical features of polycystic ovary syndrome phenotypes in women with normogonadotropic anovulation in reproductive age. Journal of Obstetrics and Women’s Diseases. 2019;68(3):7–14. (In Russ.). DOI: 10.17816/JOWD6837-14

[6] Абашова Е.И., Шалина М.А., Мишарина Е.В. и др. Клинические особенности фенотипов синдрома поликистозных яичников у женщин с нормогонадотропной ановуляцией в репродуктивном возрасте//Журнал акушерства и женских болезней. 2019. Т. 68. No. 3. С. 7–14. (In Russ.). DOI: 10.17816/JOWD6837-14

[7] Williams T, Mortada R, Porter S. Diagnosis and treatment of polycystic Ovary Syndrome. Am Fam Physician. 2016;94(2):106–113.

[8] Williams T., Mortada R., Porter S. Diagnosis and treatment of polycystic ovary syndrome//Am. Fam. Physician. 2016. Vol. 94. No. 2. P. 106–113.

[9] Lizneva D, Suturina L, Walker W, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15. DOI: 10.1016/j.fertnstert.2016.05.003

[10] Lizneva D., Suturina L., Walker W. et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome//Fertil. Steril. 2016. Vol. 106. No. 1. P. 6–15. DOI: 10.1016/j.fertnstert.2016.05.003

[11] Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–2855. DOI: 10.1093/humrep/dew218

[12] Bozdag G., Mumusoglu S., Zengin D. et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis//Hum. Reprod. 2016. Vol. 31. No. 12. P. 2841–2855. DOI: 10.1093/humrep/dew218

[13] DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83(5):1454–1460. DOI: 10.1016/j.fertnstert.2004.11.070

[14] DeUgarte C.M., Bartolucci A.A., Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment//Fertil. Steril. 2005. Vol. 83. No. 5. P. 1454–1460. DOI: 10.1016/j.fertnstert.2004.11.070

[15] Norman RJ, Masters L, Milner CR, et al. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod. 2001;16(9):1995–1998. DOI: 10.1093/humrep/16.9.1995

[16] Norman R.J., Masters L., Milner C.R. et al. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome//Hum. Reprod. 2001. Vol. 16. No. 9. P. 1995–1998. DOI: 10.1093/humrep/16.9.1995

[17] Krentz AJ, von Mühlen D, Barrett-Connor E. Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease. Menopause. 2007;14(2):284–292. DOI: 10.1097/GME.0b013e31802cc7ab

[18] Krentz A.J., von Mühlen D., Barrett-Connor E. Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease//Menopause. 2007. Vol. 14. No. 2. P. 284–292. DOI: 10.1097/GME.0b013e31802cc7ab

[19] Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111(8):607–613. DOI: 10.1016/s0002-9343(01)00948-2

[20] Legro R.S., Kunselman A.R., Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome//Am. J. Med. 2001. Vol. 111. No. 8. P. 607–613. DOI: 10.1016/s0002-9343(01)00948-2

[21] Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf). 2000;52(5):595–600. DOI: 10.1046/j.1365-2265.2000.01000.x

[22] Wild S., Pierpoint T., McKeigue P., Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study//Clin. Endocrinol. (Oxf). 2000. Vol. 52. No. 5. P. 595–600. DOI: 10.1046/j.1365-2265.2000.01000.x

[23] Jedel E, Waern M, Gustafson D, et al. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Hum Reprod. 2010;25(2):450–456. DOI: 10.1093/humrep/dep384

[24] Jedel E., Waern M., Gustafson D. et al. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index//Hum. Reprod. 2010. Vol. 25. No. 2. P. 450–456. DOI: 10.1093/humrep/dep384

[25] Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16(4):347–363. DOI: 10.1093/humupd/dmq001

[26] Moran L.J., Misso M.L., Wild R.A., Norman R.J. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis//Hum. Reprod. Update. 2010. Vol. 16. No. 4. P. 347–363. DOI: 10.1093/humupd/dmq001

[27] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. DOI: 10.1016/j.fertnstert.2003.10.004

[28] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome//Fertil. Steril. 2004. Vol. 81. No. 1. P. 19–25. DOI: 10.1016/j.fertnstert.2003.10.004

[29] Chernukha GE, Blinova IV, Kuprashvili MI. Endocrine and metabolic characteristics of patients with different phenotypes of polycystic ovary syndrome. Obstetrics and Gynecology. 2011;(2):70–76. (In Russ.)

[30] Чернуха Г.Е., Блинова И.В., Купрашвили М.И. Эндокринно-метаболические характеристики больных с различными фенотипами синдрома поликистозных яичников//Акушерство и гинекология. 2011. № 2. С. 70–76. (In Russ.)

[31] Mortada R, Williams T. Metabolic Syndrome: Polycystic Ovary Syndrome. FP Essent. 2015;435:30–42.

[32] Mortada R., Williams T. Metabolic Syndrome: Polycystic Ovary Syndrome//FP Essent. 2015. Vol. 435. P. 30–42.

[33] Ehrmann DA, Liljenquist DR, Kasza K, et al.; PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(1):48–53. DOI: 10.1210/jc.2005-1329

[34] Ehrmann D.A., Liljenquist D.R., Kasza K. et al.; PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome//J. Clin. Endocrinol. Metab. 2006. Vol. 91. No. 1. P. 48–53. DOI: 10.1210/jc.2005-1329

[35] Brower M, Brennan K, Pall M, Azziz R. The severity of menstrual dysfunction as a predictor of insulin resistance in PCOS. J Clin Endocrinol Metab. 2013;98(12):E1967–71. DOI: 10.1210/jc.2013-2815

[36] Brower M., Brennan K., Pall M., Azziz R. The severity of menstrual dysfunction as a predictor of insulin resistance in PCOS//J. Clin. Endocrinol. Metab. 2013. Vol. 98. No. 12. P. E1967–1971. DOI: 10.1210/jc.2013-2815

[37] Kim JJ, Hwang KR, Choi YM, et al. Complete phenotypic and metabolic profiles of a large consecutive cohort of untreated Korean women with polycystic ovary syndrome. Fertil Steril. 2014;101(5):1424–1430. DOI: 10.1016/j.fertnstert.2014.01.049

[38] Kim J.J., Hwang K.R., Choi Y.M. et al. Complete phenotypic and metabolic profiles of a large consecutive cohort of untreated Korean women with polycystic ovary syndrome//Fertil. Steril. 2014. Vol. 101. No. 5. P. 1424–1430. DOI: 10.1016/j.fertnstert.2014.01.049

[39] Welt CK, Gudmundsson JA, Arason G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab. 2006;91(12):4842–4848. DOI: 10.1210/jc.2006-1327

[40] Welt C.K., Gudmundsson J.A., Arason G. et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features//J. Clin. Endocrinol Metab. 2006. Vol. 91. No. 12. P. 4842–4848. DOI: 10.1210/jc.2006-1327

[41] Diamanti-Kandarakis E, Panidis D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol (Oxf). 2007;67(5):735–742. DOI: 10.1111/j.1365-2265.2007.02954.x

[42] Diamanti-Kandarakis E., Panidis D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS//Clin Endocrinol (Oxf). 2007. Vol. 67. No. 5. P. 735–742. DOI: 10.1111/j.1365-2265.2007.02954.x

[43] Carmina E, Chu MC, Longo RA, et al. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab. 2005;90(5):2545–2549. DOI: 10.1210/jc.2004-2279

[44] Carmina E., Chu M.C., Longo R.A. et al. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters//J. Clin. Endocrinol. Metab. 2005. Vol. 90. No. 5. P. 2545–2549. DOI: 10.1210/jc.2004-2279

[45] Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2009;15(4):477–488. DOI: 10.1093/humupd/dmp008

[46] Moran L., Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome//Hum. Reprod. Update. 2009. Vol. 15. No. 4. P. 477–488. DOI: 10.1093/humupd/dmp008

[47] Misharina EV, Borodina VL, Glavnova OB, et al. Insulin resistance and hyperinsulinemia. Journal of Obstetrics and Women’s Diseases. 2016;65(1):75–86. (In Russ.). DOI: 10.17816/JOWD65175-86

[48] Мишарина Е.В., Бородина В.Л., Главнова О.Б. и др. Инсулинорезистентность и гиперандрогенемия//Журнал акушерства и женских болезней. 2016. Т. 65. № 1. С. 75–86. (In Russ.). DOI: 10.17816/JOWD65175-86

[49] Mehrabian F, Khani B, Kelishadi R, Kermani N. The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females. J Res Med Sci. 2011;16(6):763–769.

[50] Mehrabian F., Khani B., Kelishadi R., Kermani N. The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females//J. Res. Med. Sci. 2011. Vol. 16. No. 6. P. 763–769.

[51] Goverde AJ, van Koert AJ, Eijkemans MJ, et al. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod. 2009;24(3):710–717. DOI: 10.1093/humrep/den433

[52] Goverde A.J., van Koert A.J., Eijkemans M.J. et al. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria//Hum. Reprod. 2009. Vol. 24. No. 3. P. 710–717. DOI: 10.1093/humrep/den433

[53] Di Fede G, Mansueto P, Longo RA, et al. Influence of sociocultural factors on the ovulatory status of polycystic ovary syndrome. Fertil Steril. 2009;91(5):1853–1856. DOI: 10.1016/j.fertnstert.2008.02.161

[54] Di Fede G., Mansueto P., Longo R.A. et al. Influence of sociocultural factors on the ovulatory status of polycystic ovary syndrome//Fertil. Steril. 2009. Vol. 91. No. 5. P. 1853–1856. DOI: 10.1016/j.fertnstert.2008.02.161

[55] Melo AS, Vieira CS, Romano LG, et al. The frequency of metabolic syndrome is higher among PCOS Brazilian women with menstrual irregularity plus hyperandrogenism. Reprod Sci. 2011;18(12):1230–1236. DOI: 10.1177/1933719111414205

[56] Melo A.S., Vieira C.S., Romano L.G. et al. The frequency of metabolic syndrome is higher among PCOS Brazilian women with menstrual irregularity plus hyperandrogenism//Reprod. Sci. 2011. Vol. 18. No. 12. P. 1230–1236. DOI: 10.1177/1933719111414205

[57] Wijeyaratne CN, Seneviratne Rde A, Dahanayake S, et al. Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic. Hum Reprod. 2011;26(1):202–213. DOI: 10.1093/humrep/deq310

[58] Wijeyaratne C.N., Seneviratne Rde A., Dahanayake S. et al. Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS): results of a large database from a specialist Endocrine Clinic//Hum. Reprod. 2011. Vol. 26. No. 1. P. 202–213. DOI: 10.1093/humrep/deq310

[59] Jones H, Sprung VS, Pugh CJ, et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2012;97(10):3709–3716. DOI: 10.1210/jc.2012-1382

[60] Jones H., Sprung V.S., Pugh C.J. et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance//J. Clin. Endocrinol. Metab. 2012. Vol. 97. No. 10. P. 3709–3716. DOI: 10.1210/jc.2012-1382

[61] Salim R, Serhal P. IVF in Polycystic ovary syndrome. In: Diagnosis and Management of Polycystic Ovary Syndrome. Farid NR, Diamantis-Kandarakis E, editors. Boston: Springer US; 2009. P. 253–258. [cited 2021 May 12]. Available from: https://link.springer.com/content/pdf/10.1007 %2F978-0-387-09718-3.pdf. DOI: 10.1007/978-0-387-09718-3_21

[62] Salim R., Serhal P. IVF in Polycystic ovary syndrome. In: Diagnosis and Management of Polycystic Ovary Syndrome / eds. N.R. Farid, E. Diamantis-Kandarakis. Boston: Springer US, 2009. P. 253–258. [дата обращения 12.05.2021]. Доступ по ссылке: https://link.springer.com/content/pdf/10.1007 %2F978-0-387-09718-3.pdf. DOI: 10.1007/978-0-387-09718-3_21

[63] Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Arch Gynecol Obstet. 2016;293(2):447–456. DOI: 10.1007/s00404-015-3889-5

[64] Jamil A.S., Alalaf S.K., Al-Tawil N.G., Al-Shawaf T. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria//Arch. Gynecol. Obstet. 2016. Vol. 293. No. 2. P. 447–456. DOI: 10.1007/s00404-015-3889-5

[65] Nikolaenkov IP. Antimyllerov gormon v patogeneze sindroma polikistoznykh yaichnikov. [dissertation abstract] Saint Petersburg; 2014. (In Russ.). [cited 2021 May 12]. Available from: https://www.dissercat.com/content/antimyullerov-gormon-v-patogeneze-sindroma-polikistoznykh-yaichnikov. DOI: 10.1007/978-0-387-09718-3_21

[66] Николаенков И.П. Антимюллеров гормон в патогенезе синдрома поликистозных яичников: авотреф. дис. ... кандидат медицинских наук. Санкт-Петербург, 2014. [дата обращения 12.05.2021]. Доступ по ссылке: https://www.dissercat.com/content/antimyullerov-gormon-v-patogeneze-sindroma-polikistoznykh-yaichnikov. DOI: 10.1007/978-0-387-09718-3_21

[67] Zhang HY, Zhu FF, Xiong J, et al. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population. BJOG. 2009;116(12):1633–1639. DOI: 10.1111/j.1471-0528.2009.02347.x

[68] Zhang H.Y., Zhu F.F., Xiong J. et al. Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population//BJOG. 2009. Vol. 116. No. 12. P. 1633–1639. DOI: 10.1111/j.1471-0528.2009.02347.x

[69] Guastella E, Longo RA, Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril. 2010;94(6):2197–2201. DOI: 10.1016/j.fertnstert.2010.02.014

[70] Guastella E., Longo R.A., Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes//Fertil. Steril. 2010. Vol. 94. No. 6. P. 2197–2201. DOI: 10.1016/j.fertnstert.2010.02.014

[71] Panidis D, Tziomalos K, Papadakis E, et al. Associations of menstrual cycle irregularities with age, obesity and phenotype in patients with polycystic ovary syndrome. Hormones (Athens). 2015;14(3):431–437. DOI: 10.14310/horm.2002.1593

[72] Panidis D., Tziomalos K., Papadakis E. et al. Associations of menstrual cycle irregularities with age, obesity and phenotype in patients with polycystic ovary syndrome//Hormones (Athens). 2015. Vol. 14. No. 3. P. 431–437. DOI: 10.14310/horm.2002.1593

[73] Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95(5):2038–2049. DOI: 10.1210/jc.2009-2724

[74] Wild R.A., Carmina E., Diamanti-Kandarakis E. et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society//J. Clin. Endocrinol. Metab. 2010. Vol. 95. No. 5. P. 2038–2049. DOI: 10.1210/jc.2009-2724

[75] Sha T, Wang X, Cheng W, Yan Y. A meta-analysis of pregnancy-related outcomes and complications in women with polycystic ovary syndrome undergoing IVF. Reprod Biomed Online. 2019;39(2):281–293. DOI: 10.1016/j.rbmo.2019.03.203

[76] Sha T., Wang X., Cheng W., Yan Y. A meta-analysis of pregnancy-related outcomes and complications in women with polycystic ovary syndrome undergoing IVF//Reprod. Biomed. Online. 2019. Vol. 39. No. 2. P. 281–293. DOI: 10.1016/j.rbmo.2019.03.203

[77] March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544–551. DOI: 10.1093/humrep/dep399

[78] March W.A., Moore V.M., Willson K.J. et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria//Hum. Reprod. 2010. Vol. 25. No. 2. P. 544–551. DOI: 10.1093/humrep/dep399

[79] Nikolayenkov IP, Kuzminykh TU, Tarasova MA, Seryogina DS. Features of the course of pregnancy in women with polycystic ovary syndrome. Journal of Obstetrics and Women’s Diseases. 2020;69(5):105–112. DOI: 10.17816/JOWD695105-112

[80] Николаенков И.П., Кузьминых Т.У., Тарасова М.А., Серегина Д.С. Особенности течения беременности у пациенток с синдромом поликистозных яичников//Журнал акушерства и женских болезней. 2020. Т. 69. № 5. С. 105–112. DOI: 10.17816/JOWD695105-112

[81] Wei D, Shi Y, Li J, Wang Z, et al. Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome. Hum Reprod. 2017;32(2):354–361. DOI: 10.1093/humrep/dew325

[82] Wei D., Shi Y., Li J. et al. Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome//Hum. Reprod. 2017. Vol. 32. No. 2. P. 354–361. DOI: 10.1093/humrep/dew325

[83] Cela V, Obino MER, Alberga Y, et al. Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes. Gynecol Endocrinol. 2018;34(6):518–523. DOI: 10.1080/09513590.2017.1412429

[84] Cela V., Obino M.E.R., Alberga Y. et al. Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes//Gynecol. Endocrinol. 2018. Vol. 34. No. 6. P. 518–523. DOI: 10.1080/09513590.2017.1412429

[85] Celkovich LS, Ivanova TV, Ibragimova AR, et al. Sravnitel’naya ocenka protokolov EKO u zhenshchin s razlichnymi klinicheskimi variantami techeniya sindroma polikistoznyh yaichnikov. Aspirantskij vestnik Povolzh’ya. 2017;17(5–6):97–103. (In Russ.)

[86] Целкович Л.С., Иванова Т.В., Ибрагимова А.Р. и др. Сравнительная оценка протоколов ЭКО у женщин с различными клиническими вариантами течения синдрома поликистозных яичников//Аспирантский вестник Поволжья. 2017. Т. 17. № 5–6. C. 97–103.

[87] Bezirganoglu N, Seckin KD, Baser E, et al. Isolated polycystic morphology: Does it affect the IVF treatment outcomes? J Obstet Gynaecol. 2015;35(3):272–274. DOI: 10.3109/01443615.2014.948407

[88] Bezirganoglu N., Seckin K.D., Baser E. et al. Isolated polycystic morphology: Does it affect the IVF treatment outcomes?//J. Obstet. Gynaecol. 2015. Vol. 35. No. 3. P. 272–274. DOI: 10.3109/01443615.2014.948407

[89] De Vos M, Pareyn S, Drakopoulos P, et al. Cumulative live birth rates after IVF in patients with polycystic ovaries: phenotype matters. Reprod Biomed Online. 2018;37(2):163–171. DOI: 10.1016/j.rbmo.2018.05.003

[90] De Vos M., Pareyn S., Drakopoulos P. et al. Cumulative live birth rates after IVF in patients with polycystic ovaries: phenotype matters//Reprod. Biomed. Online. 2018. Vol. 37. No. 2. P. 163–171. DOI: 10.1016/j.rbmo.2018.05.003

[91] Kjerulff LE, Sanchez-Ramos L, Duffy D. Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis. Am J Obstet Gynecol. 2011;204(6):558.e1–6. DOI: 10.1016/j.ajog.2011.03.021

[92] Kjerulff L.E., Sanchez-Ramos L., Duffy D. Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis//Am. J. Obstet. Gynecol. 2011. Vol. 204. No. 6. P. 558.e1–6. DOI: 10.1016/j.ajog.2011.03.021

[93] Wan HL, Hui PW, Li HW, Ng EH. Obstetric outcomes in women with polycystic ovary syndrome and isolated polycystic ovaries undergoing in vitro fertilization: a retrospective cohort analysis. J Matern Fetal Neonatal Med. 2015;28(4):475–478. DOI: 10.3109/14767058.2014.921673

[94] Wan H.L., Hui P.W., Li H.W., Ng E.H. Obstetric outcomes in women with polycystic ovary syndrome and isolated polycystic ovaries undergoing in vitro fertilization: a retrospective cohort analysis//J. Matern. Fetal. Neonatal. Med. 2015. Vol. 28. No. 4. P. 475–847. DOI: 10.3109/14767058.2014.921673

[95] Thakre N, Homburg R. A review of IVF in PCOS patients at risk of ovarian hyperstimulation syndrome. Expert Rev Endocrinol Metab. 2019;14(5):315–319. DOI: 10.1080/17446651.2019.1631797

[96] Thakre N., Homburg R. A review of IVF in PCOS patients at risk of ovarian hyperstimulation syndrome//Expert. Rev. Endocrinol. Metab. 2019. Vol. 14. No. 5. P. 315–319. DOI: 10.1080/17446651.2019.1631797

[97] Lee TH, Liu CH, Huang CC, et al. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod. 2008;23(1):160–167. DOI: 10.1093/humrep/dem254

[98] Lee T.H., Liu C.H., Huang C.C. et al. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles//Hum. Reprod. 2008. Vol. 23. No. 1. P. 160–167. DOI: 10.1093/humrep/dem254

[99] Lin K, Coutifaris C. In vitro fertilization in the polycystic ovary syndrome patient: an update. Clin Obstet Gynecol. 2007;50(1):268–276. DOI: 10.1097/GRF.0b013e3180305fe4

[100] Lin K., Coutifaris C. In vitro fertilization in the polycystic ovary syndrome patient: an update//Clin. Obstet. Gynecol. 2007. Vol. 50. No. 1. P. 268–276. DOI: 10.1097/GRF.0b013e3180305fe4

[101] Tso LO, Costello MF, Albuquerque LE, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2014;2014(11):CD006105. Corrected and republished from: Cochrane Database Syst Rev. 2020;12:CD006105. DOI: 10.1002/14651858.CD006105.pub3

[102] Tso L.O., Costello M.F., Albuquerque L.E. et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome//Cochrane Database Syst. Rev. 2014. Vol. 2014. No. 11. P. CD006105. Corrected and republished from: Cochrane Database Syst. Rev. 2020;12:CD006105. DOI: 10.1002/14651858.CD006105.pub3

[103] Gleicher N, Kushnir VA, Darmon SK, et al. New PCOS-like phenotype in older infertile women of likely autoimmune adrenal etiology with high AMH but low androgens. J Steroid Biochem Mol Biol. 2017;167:144–152. DOI: 10.1016/j.jsbmb.2016.12.004

[104] Gleicher N., Kushnir V.A., Darmon S.K. et al. New PCOS-like phenotype in older infertile women of likely autoimmune adrenal etiology with high AMH but low androgens//J. Steroid. Biochem. Mol. Biol. 2017. Vol. 167. P. 144–152. DOI: 10.1016/j.jsbmb.2016.12.004

[105] Bozdag G, Mumusoglu S, Coskun ZY, et al. Anti-Müllerian hormone as a diagnostic tool for PCOS under different diagnostic criteria in an unselected population. Reprod Biomed Online. 2019;39(3):522–529. DOI: 10.1016/j.rbmo.2019.04.002.

[106] Bozdag G., Mumusoglu S., Coskun Z.Y. et al. Anti-Müllerian hormone as a diagnostic tool for PCOS under different diagnostic criteria in an unselected population//Reprod. Biomed. Online. 2019. Vol. 39. No. 3. P. 522–529. DOI: 10.1016/j.rbmo.2019.04.002.

RIGHTS & PERMISSIONS

Eсо-Vector